Craft
  • Home
  •  / Apellis Pharmaceuticals
Apellis Pharmaceuticals

Apellis Pharmaceuticals

Facility Space, sq. ft.

105.3 K

FY, 2021

Revenue

$66.6 M

FY, 2021

Market Capitalization

$4.5 B

2023-01-06

Apellis Pharmaceuticals Summary

Company summary

Overview
Apellis Pharmaceuticals is a biopharmaceutical company focused on the development of therapeutic compounds. Its products are used to treat disease through the inhibition of the complement system, at the level of C3, the central protein in the complement cascade. The company caters to ophthalmology, rare disease, and research areas.
Type
Public
Status
Active
Founded
2009
HQ
Waltham, MA, US | view all locations
Website
https://apellis.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key people

  • Cedric Francois

    Cedric Francois, Co-Founder & Chief Executive Officer/President

  • Pascal Deschatelets

    Pascal Deschatelets, Co-Founder & Chief Scientific Officer

  • Jeffrey Eisele

    Jeffrey Eisele, Chief Development Officer

  • Federico Grossi

    Federico Grossi, Chief Medical Officer

Operating MetricsView all

Clinical Programs

6
14.3%

FY, 2021

Facility Space, sq. ft.

105.3K

FY, 2021

LocationsView all

5 locations detected

  • Waltham, MA HQ

    United States

    100 5th Avenue

  • San Francisco, CA

    United States

    720 Market St #500, San Francisco

  • Watertown, MA

    United States

    65 Grove St #302

  • München, BY

    Germany

    Landsberger Str. 302

  • Zug, ZG

    Switzerland

    Zählerweg 10

Apellis Pharmaceuticals Financials

Summary financials

Revenue (Q3, 2022)
$22.1M
Gross profit (Q3, 2022)
$20.7M
Net income (Q3, 2022)
($191.3M)
Cash (Q3, 2022)
$584.2M
EBIT (Q3, 2022)
($152.9M)
Enterprise value
$4.1B

Footer menu